课题基金 / 基金详情

Adaptation of Cognitive Enhancement Therapy for persons at Psychosis High Risk

Adaptation of Cognitive Enhancement Therapy for persons at Psychosis High Risk
针对精神病高危人群的认知增强疗法的调整
批准号:
8976169
负责人:
MATCHERI S. KESHAVAN
金额:
$26.1万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-12-01 至 2017-11-30

项目摘要

项目成果

MATCHERI S. KESHAVAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Persons at clinical high risk (CHR) state for psychosis are characterized by attenuated or transient psychotic episodes, trait vulnerability and functional deficits. If untreated, a significant proportion of CHR individuals have adverse outcomes, including conversion to psychosis, other psychopathology and functional deterioration. Despite enhanced CHR research focus over the past decade there are few established prevention approaches. This proposal seeks to develop, evaluate feasibility, acceptability and obtain preliminary data on efficacy of a novel manualized approach for cognitive enhancement, the Cognition for Learning and for Understanding Everyday Social Situations (CLUES) in individuals at clinical high risk (CHR) for psychosis. This approach is based on the principles and approaches of cognitive enhancement therapy (CET), shown by this research group to have efficacy, generalizability to functional outcome, durability and possible neuroprotective effects. In Phase 1 (0-6 months) we will adapt CET techniques to the symptomatic, functional, and developmental features of CHR, train staff and develop assessment procedures and a manual for the CLUES intervention with the help of a focus group and input from an advisory group of experts. In phase 2, using a feasibility trial (n=8) we will assess acceptability, tolerability, treatment adherence, treatment fidelity, and obtain preliminary evidence of target engagement (i.e. change in cognition and social cognition). .In Phase 3 (19-36 months) we will conduct a randomized control trial to generate pilot efficacy, generalization to functional outcome, durability and tolerability data on CLUES in CHR individuals (n=30). These data will serve as a prerequisite to a later, larger-scale intervention study of CLUES in the CHR population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS)
4/5: Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)
4/5: Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)
Longitudinal trajectories in treated and untreated schizophrenia
  • 批准号:
    10306962
  • 项目类别:
  • 资助金额:
    $64.17万
  • 财政年份:
    2021
  • 负责人:
    MATCHERI S. KESHAVAN
  • 依托单位:
海外基金